The acute respiratory distress syndrome (ARDS) market has witnessed significant impact and advancements. ARDS is a life-threatening condition that primarily affects the lungs, leading to severe breathing difficulties. Advanced ventilation techniques and supportive care have improved patient outcomes. Additionally, pharmaceutical innovations, such as surfactant therapy and anti-inflammatory agents, show promise. The market focuses on personalized treatment strategies and reducing the mortality rate. These advancements bring hope for better management of ARDS, enhancing the quality of patient care.
Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-acute-respiratory-distress-syndrome-ards-market
Data Bridge Market Research analyses that the Europe Acute Respiratory Distress Syndrome (ARDS) Market was valued at USD 2,560.34 million in 2021 and is expected to reach a value of USD 5,291.89 million by 2029, at a CAGR of 9.5% during the forecast period of 2022-2029. The rising incidence of acute respiratory distress syndrome (ARDS) is a crucial market driver. As more individuals are affected by this life-threatening condition, a growing demand for innovative treatments and therapies propels market growth.
Key Findings of the Study
Aging population is expected to drive the market's growth rate
The elderly population's increased susceptibility to acute respiratory distress syndrome (ARDS) is significant in market expansion. Individuals often experience weakened lung function and reduced respiratory capacity with advancing age, making them more vulnerable to ARDS. As the global population ages, the prevalence of ARDS among older adults is on the rise, creating a greater demand for medical interventions and treatments, thereby expanding the ARDS market to address the unique needs of this demographic.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
|
|
Market Players Covered
|
Drägerwerk AG & Co. KGaA (Germany), Fisher & Paykel Healthcare Limited (New Zealand), LivaNova PLC (U.K.), Gilead Sciences, Inc. (U.S.), Fresenius SE & Co. KGaA (Germany), Armstrong Medical (U.K.), Smiths Medical (U.S.), ResMed (U.S.), Medtronic (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Hamilton Medical (Switzerland), nice Neotech Medical Systems Pvt. Ltd. (India), Pfizer Inc. (U.S.), Terumo Medical Corporation (Japan), Getinge AB (Sweden), EUROSETS (Italy)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe acute respiratory distress syndrome (ARDS) market is segmented on the basis of cause, type, route of administration, end user, and distribution channel.
- On the basis of cause, the Europe acute respiratory distress syndrome (ARDS) market is segmented into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia, and others.
- On the basis of type, the Europe acute respiratory distress syndrome (ARDS) market is segmented into diagnosis, and treatment.
- On the basis of route of administration, the Europe acute respiratory distress syndrome (ARDS) market is segmented into oral, parenteral, and other.
- On the basis of end users, the Europe acute respiratory distress syndrome (ARDS) market is segmented into hospitals, specialty clinics, home healthcare, and others.
- On the basis of distribution channel, the Europe acute respiratory distress syndrome (ARDS) market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others.
Major Players
Data Bridge Market Research recognizes the following companies as the Europe acute respiratory distress syndrome (ARDS) market players in Europe acute respiratory distress syndrome (ARDS) market are Drägerwerk AG & Co. KGaA (Germany), Fisher & Paykel Healthcare Limited (New Zealand), LivaNova PLC (U.K.), Gilead Sciences, Inc. (U.S.), Fresenius SE & Co. KGaA (Germany), Armstrong Medical (U.K.).
Market Developments
- In April 2022, the FDA approved Direct Biologics for a groundbreaking Phase 3 clinical trial. This trial aims to evaluate the efficacy of the investigational EV Drug ExoFlow in treating acute respiratory distress syndrome (ARDS). This significant milestone paves the way for advanced research and potential therapeutic solutions to address a critical medical condition, offering hope for improved outcomes for ARDS patients.
- In January 2022, Veru announced that its drug, Sabizabulin, received a fast-track designation from the FDA for treating hospitalized COVID-19 patients at high risk of developing acute respiratory distress syndrome (ARDS). This designation expedites the drug's development and regulatory process, recognizing its potential to address a critical need in managing severe COVID-19 cases and preventing the onset of ARDS in vulnerable patients.
- In February 2021, Pfizer Inc. CentreOne introduced a campaign showcasing their extensive selection of complex API compounds and intermediates tailored for drug product developers and manufacturers. This strategic initiative aimed to bolster their presence in the U.S. market. By highlighting their diverse API offerings, Pfizer Inc. CentreOne aimed to provide enhanced support and solutions to pharmaceutical companies, contributing to their growth and success within the U.S. pharmaceutical landscape.
- In January 2020, ResMed introduced the AirTouch N20 Foam CPAP Mask, featuring their first-ever nasal memory foam cushion. This innovation prioritized patient comfort and convenience as the cushion didn't require cleaning when replaced on schedule. The AirTouch N20 added to ResMed's range of user-friendly and comfortable masks. This product portfolio expansion allowed ResMed to offer enhanced solutions, catering to a broader spectrum of patient needs in the respiratory care market.
Regional Analysis
Geographically, the countries covered in the Europe acute respiratory distress syndrome (ARDS) market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe,
As per Data Bridge Market Research analysis:
Germany is the dominant region in the Europe acute respiratory distress syndrome (ARDS) market during the forecast period 2022-2029
Germany dominates the European acute respiratory distress syndrome (ARDS) market, driven by a robust biotechnology and pharmaceutical sector. The region's increasing research activities contribute to ARDS treatment and technology advancements. Consequently, this growth in the biopharmaceutical industry fosters demand for ARDS products across Europe. Germany's leadership role underscores its significance in shaping the ARDS market landscape on the continent.
For more detailed information about the Europe acute respiratory distress syndrome (ARDS) market report, click here – https://www.databridgemarketresearch.com/reports/europe-acute-respiratory-distress-syndrome-ards-market
